The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1192-1198

  Rietbergen, John B W ^a   Hoedemaeker, Robert F ^a   Boeken Kruger, Arto E ^a   Kirkels, Wim J ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Prostatic neoplasms; Staging; Tumor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FINGER; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECTUM; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0032853499     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61630-6     Document Type: Article

References (23)

1. Visser, O., Coebergh, J. W. W., Schouten, L. J. and van Dijck, J. A. A. M.: Incidence of Cancer in The Netherlands 1994: the Sixth Report of The Netherlands Cancer Registry. Utrecht: Vereniging van Integrale Kankercentra, 1997.
2. Schellhammer, P. F., Sharifi, R., Block, N. L., Soloway, M. S., Venner, P. M., Patterson, A. L., Sarosdy, M. F., Vogelzang, N. J., Schellenger, J. J., Kolvenbag, G. J. and the Casodex Combination Study Group: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology, 50: 330, 1997.
3. Franks, L. M.: Latent carcinoma of the prostate. J. Path. Bact., 68: 603, 1954.
4. Montie, J. E., Wood, D. P., Pontes, J. E., Boyett, J. M. and Levin, H. S.: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer, 63: 381, 1989.
5. Kabalin, J. N., McNeal, J. E., Price, H. M., Freiha, F. S. and Stanley, T. A.: Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J. Urol., 141: 1091, 1989.
6. Ohori, M., Wheeler, T. M., Dunn, J. K., Stamey, T. A. and Scardino, P. T.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol., 152: 1714, 1994.
7. Humphrey, P. A., Keetch, D. W., Smith, D. S., Shepherd, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
8. Auvinen, A., Rietbergen, J. B., Denis, L. J., Schröder, F. H., Prorok, P. C. and The International Prostate Cancer Screening Trial Evaluation Group: Prospective evaluation plan for randomized trials of prostate cancer screening. J. Med. Screening, 3: 97, 1996.
9. Visser, O. and Horenblas, S.: Incidence and treatment of prostate cancer in the region of the Comprehensive Cancer Center Amsterdam (CCCA), 1989-1994. Ned. Tijdschr. Geneeskd., 140: 2627, 1996.
10. Lee, F., Gray, J. M., McLeary, R. D., Meadows, T. R., Kumasaka, G. H., Borlaza, G. S., Straub, W. H., Lee, F., Jr., Solomon, M. H. and McHugh, T. A.: Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate, 7: 117, 1985.
11. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K. and Pavone-Macaluso, M.: The TNM classification of prostate cancer. Prostate, suppl., 4: 129, 1992.
12. Chybowski, F. M., Keller, J. J., Bergstralh, E. J. and Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145: 313, 1991.
13. Kemp, P. M., Maguire, G. A. and Bird, N. J.: Which patients with prostatic carcinoma require a staging bone scan? Brit. J. Urol., 79: 611, 1997.
14. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
15. Blute, M. L., Zincke, H. and Farrow, G. M.: Long-term follow-up of young patients with stage A adenocarcinoma of the prostate. J. Urol., 136: 840, 1986.
16. Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F. and Fine, J.: Long-term survival among men with conservatively treated localized prostate cancer. J.A.M.A., 274: 626, 1995.
17. Hoedemaeker, R. F., Rietbergen, J. B. W., Kranse, R., Kwast van der Th.H. and Schröder, F. H.: Comparison of pathologic characteristics of T1C and non-T1C cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J. Urol., 15: 339, 1997.
18. Kojima, M., Troncoso, P. and Babaian, R. J.: Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology, 45: 807, 1995.
19. Bostwick, D. G.: Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Amer. J. Surg. Path., 18: 796, 1994.
20. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 152: 1732, 1994.
21. Mettlin, C., Murphy, G. P., Lee, F., Littrup, P. J., Chesley, A., Babaian, R., Badalament, R., Kane, R. A. and Mostofi, F. K. and The Investigators of the American Cancer Society-National Prostate Cancer Detection Project: Characteristics of prostate cancers detected in a multimodality early detection program. Cancer, 72: 1701, 1993.
22. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
23. Pound, C. R., Partin, A. W., Epstein, J. I. and Walsh, P. C.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. N. Amer., 24: 395, 1997.